Jesper Høiland is SciBase’s new Chairman of the Board.
SciBase develops and commercializes Nevisense, a point-of-care platform that combines artificial intelligence and advanced Electrical Impedance Spectroscopy (EIS) to detect melanoma.
Mr. Høiland has more than 25 years of experience in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US). He will succeed Tord Lendau.
“We are happy about the election of Jesper Høiland as the new Chairman of our board,” says Pia Renaudin, CEO of SciBase. “He will bring valuable insights and experience especially from the US market, which is our primary focus. We also welcome, as previously communicated, Robert Molander as new member of the Board. “
She adds, “We extend our deepest thanks to Tord for his exceptional leadership and commitment to SciBase. He has been instrumental in SciBase progress. I also want to take the opportunity to thank both Dr Matt Leavitt and Jvalini Dwarkasing for their support in driving SciBase forward as they now retire as members of the Board. “
In addition, Leda Beaty is the new Head of U.S. Commercial Operations at SciBase.
Ms. Beaty joins Scibase from DermTech Inc., where she was Senior National Director and responsible for creating partnerships with clinicians, building strategic partnerships, and generating market expansion in dermatology. She also worked at Aventis, Amgen, and Arthrex.
